EASL Selects Albireo’s A4250 Data for Late Breaker Presentation

April 5, 2017



— Preliminary Data from Phase 2 Trial of Albireo’s Lead Product Candidate in Children with Chronic Cholestasis to be Presented at The International Liver Congress™ 2017 —

BOSTON — April 5, 2017 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data from the ongoing Phase 2 study of its lead product candidate A4250 in children with cholestatic liver disease has been selected by the European Association for the Study of the Liver (EASL) for an oral presentation during the late breaker session at The International Liver Congress (ILC) 2017 being held April 19-23, 2017, at the RAI Amsterdam in Amsterdam.


Details of the presentation are as follows:

Title: The Ileal Bile Acid Transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases – an ongoing multiple dose, open-label, multicentre study

Session: Late Breaker

Date / Time: Saturday, April 22, 4:45 p.m. – 5:00 p.m. CET

Location: Hall 5

Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology at Hannover Medical School, Germany


EASL’s ILC, now in its 52nd year, is a multi-disciplinary scientific Congress which brings more than 10,000 clinicians and scientists together annually to discuss clinical innovation and research. For more information about the conference, visit


About Albireo 

Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.


Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit




Investor Contact:

Hans Vitzthum

LifeSci Advisors, LLC.



Media Contact:

Heather Anderson

6 Degrees



Source: Albireo Pharma, Inc.

Albireo Homepage